INFLAMMATION & ITS SEQUELAE IN IBD FOLLOWING INFLIXIMAB

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 克罗恩病和溃疡性结肠炎是炎症性肠病(IBD)，与全身炎症有关。这种炎症反过来又与食欲不佳、生长障碍和青春期延迟有关。英夫利昔单抗是一种抗肿瘤坏死因子的单抗，最近已被批准用于儿科。虽然已知长期使用英夫利昔单抗可改善患者的生活质量，但短期变化尚未被研究。此外，目前尚不清楚英夫利昔单抗是否能改善与生长和青春期有关的激素水平。我们建议在注射英夫利昔单抗前、后2天和2周检测炎症迹象--血清CRP和粪便乳铁蛋白。我们还将测试与生长和青春期有关的激素水平，包括IGF-1、亮氨酸激素、雌二醇和睾酮，并确定食欲和生活质量指标的变化。这些知识将有助于确定对治疗的正常反应，并使医生能够滴定英夫利昔单抗的剂量，并就治疗结果向患者提供建议。了解与生长和青春期相关的激素的反应将更好地表征炎症对这些过程的影响，并有助于表明英夫利昔单抗是否可能改善IBD儿童的生长。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBD) that are associated with systemic inflammation. This inflammation is in turn linked to poor appetite, growth failure and delayed puberty. Infliximab is a monoclonal antibody to TNF- that has recently been approved for use in pediatrics. Though it is known that long-term use of infliximab improves patients' quality of life (QOL), the short-term changes have not been studied. Additionally, it is not known whether infliximab improves levels of hormones related to growth and puberty. We propose to test for signs of inflammation-serum CRP and fecal lactoferrin-prior to, 2 days after and 2 weeks after an infusion of infliximab. We will also test for levels of hormones related to growth and puberty-including IGF-1, leutinizing hormone, estradiol and testosterone-and determine changes in measures of appetite and QOL. Such knowledge would be useful in defining normal response to therapy and in equipping physicians to titrate doses of infliximab and counsel patients regarding what to expect from treatment. Knowing the response of hormones related to growth and puberty will better characterize the effects of inflammation on these processes and help indicate whether infliximab might improve growth in children with IBD.